Drug induced iatrogenic Cushing’s syndrome
DOI:
https://doi.org/10.18203/2320-6012.ijrms20234026Keywords:
Iatrogenic Cushing's syndrome, Glucocorticoids, Hypercortisolism, Endogenous Cushing's syndrome, Glucocorticoid-induced disorders, Glucocorticoid withdrawalAbstract
Drug-induced (iatrogenic) Cushing's syndrome results from excessive or prolonged exposure to glucocorticoids, commonly prescribed for autoimmune, inflammatory, and hematological disorders due to their anti-inflammatory, immunosuppressive, and proapoptotic effects. Despite their therapeutic benefits, these medications can lead to a range of multisystemic symptoms mirroring those of endogenous Cushing’s syndrome. This review aims to elucidate the causes, clinical presentation, diagnosis, and management of iatrogenic Cushing's syndrome, emphasizing awareness of medications that can trigger its onset. The following review covers cortisol physiology, Cushing's syndrome etiology and subtypes, hypercortisolism complications and prognosis, and strategies for glucocorticoid withdrawal. This article synthesizes key findings and recommendations, highlighting challenges and controversies in the diagnosis and treatment of iatrogenic Cushing's syndrome.
Metrics
References
Jimenez NABZ, Torres AIR, Chiquito HMC, Choez CAC. Treatment of Iatrogenic Cushing's Syndrome: Glucocorticoid Withdrawal Issues. RECIAMUC. 2020;4(4):170-9.
Hall JE. Guyton y Hall. Tratado de fisiología médica, 14 edition. Elsevier. 2021.
Huanca LKM, Catacora SC, Callisaya HJA, Loza-Murguia MG, Soto GFF. Síndrome de Cushing por consumo excesivo de corticoesteroides. Curr Opin Nurs Res. 2021;3(1):16-26.
Carroll TB, Aron DC, Findling JW, Tyrrell J. Glucocorticoides y andrógenos suprarrenales. Gardner DG, Shoback D, Editors. Greenspan. Endocrinología básica y clínica 10e. McGraw Hill. 2019.
Norris TL, Lalchandani R. Porth. Fisiopatología (10a edition). Wolters Kluwer Health. 2019.
Athimulam S, Grebe S, Bancos I. Steroid profiling in the diagnosis of mild and overt Cushing's syndrome. Best Pract Res Clin Endocrinol Metab. 2021;35(1):101488.
Sanpawithayakul K, Korbonits M. Metabolic complications of glucocorticoids - Prevention by metformin. Ann Endocrinol (Paris). 2023;84(4):483-97.
Álvarez-Hernández E, Mercado-Molina G, Barrera-Guerra RC. Validity of the Cushing's Syndrome Severity Index in Patients with Iatrogenic Cushing's Syndrome. Reumatol Clin (Engl Ed). 2021;17(6):313-7.
Hwang S, Tatsi C, Kuehn HS, Niemela JE, Stoddard J, Su Y, et al. Cushing syndrome and glucocorticoids: T-cell lymphopenia, apoptosis, and rescue by IL-21. J Allergy Clin Immunol. 2022;149(1):302-14.
Aulinas A, Valassi E, Webb SM. Pronóstico del paciente tratado de síndrome de Cushing. Endocrinología y Nutrición. 2014;61(1):52-61.
Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson J, Editors. Harrison. Principios de Medicina Interna, 21e. McGraw Hill. 2022.
Purser JD, Riachy R, Blanton LS, Belalcazar LM. Rapid development of iatrogenic Cushing syndrome in a patient on ritonavir: the adverse metabolic consequence of topical steroid use. AACE Clin Case Rep. 2020;6(6):e346-8.
Cristante J, Chabre O. Factitious, or iatrogenic but unexpected Cushing’s syndrome. Annales d’Endocrinologie. 2023;84(3):370-2.
Sachdeva S, Arora P, Kulhari A, Sardana K. Iatrogenic cushing’s syndrome due to topical steroid abuse in a child with psoriasis presenting as septicaemia. Dermatol Ther. 2020;33(4).
Khan F, Hakeem J, Raghavendra M, Das SK, Rajesham VV, Tadikonda RR. Methyl-Prednisolone and betamethasone induced iatrogenic cushing syndrome - a rare case report. Int J Pharm Res Allied Sci. 2023;12(2):40-5.
Kapoor H, Hatfield W, El Khouli R, Clark AX. Iatrogenic Cushing's syndrome on 18F-FDG-PET/CT: A pitfall in metabolic assessment of oncologic response. Clin Imaging. 2021;75:27-9.
Downloads
Published
How to Cite
Issue
Section
